Bright Minds Biosciences faces investor investigation following FDA clinical hold
Legal firm SueWallSt has launched an investigation into potential securities violations at Bright Minds Biosciences after the FDA paused a planned Phase 2 epilepsy trial.
Law firm SueWallSt is investigating potential securities law violations at Bright Minds Biosciences (NASDAQ: DRUG) following a significant decline in the company's share price. The sell-off was triggered by the FDA’s decision to place a partial clinical hold on the firm's planned Phase 2 BMB-101 trial for developmental and epileptic encephalopathies.
The regulatory action stems from findings of toxicity in mice, with the FDA citing a lack of sufficient pharmacokinetic and juvenile-toxicity data to support the enrollment of pediatric patients. While Bright Minds Biosciences stated it disagrees with the agency’s assessment, it has acknowledged that additional studies or data may be required to resolve the regulatory concerns.
The investigation aims to determine whether the company provided materially misleading information to investors regarding the progress and data supporting its BMB-101 program. Investors who incurred losses are being evaluated for potential claims, regardless of whether they have already sold their holdings.